Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations

Mitochondrion

Volumn 7, Issue SUPPL., 2007, Pages

  Bhagavan, Hemmi N ^a   Chopra, Raj K ^a  

^a Tishcon Corporation   (United States)

Author keywords

Coenzyme Q10; Coenzyme Q10 bioavailability; Plasma coenzyme Q10 concentration; Solubilized coenzyme Q10 formulations; Ubiquinol; Ubiquinone

Indexed keywords

PLACEBO; UBIDECARENONE;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG MEGADOSE; DRUG UPTAKE; HUMAN; LOW DRUG DOSE; PARKINSON DISEASE; POWDER; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SYRUP; TABLET FORMULATION;

ADMINISTRATION, ORAL; ADULT; ANIMALS; BRAIN; CHEMISTRY, PHARMACEUTICAL; CHILD; CLINICAL TRIALS; COENZYMES; HUMANS; MODELS, BIOLOGICAL; OXIDATION-REDUCTION; TABLETS; TIME FACTORS; UBIQUINONE;

EID: 34248162014     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mito.2007.03.003     Document Type: Review

References (60)

1. Beal M.F. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Rad. Res. 36 (2002) 455-460
2. Belardinelli R., Mucaj A., Lacalaprice F., Solenghi M., Seddaiu G., Principi F., Tiano L., and Littarru G.P. Coenzyme Q10 and exercise training in chronic heart failure. Eur. Heart J. 27 (2006) 2675-2681
3. Bhagavan H.N., and Chopra R.K. Potential role of ubiquinone (coenzyme Q10) in pediatric cardiomyopathy. Clin. Nutr. 24 (2005) 331-338
4. Bhagavan H.N., and Chopra R.K. Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic. Res. 40 (2006) 445-453
5. Bhagavan H.N., Chopra R.K., and Sinatra S.T. Absorption and bioavailability of coenzyme Q10. In: Ebadi M., Marwah J., and Chopra R. (Eds). Coenzyme Q10 in mitochondrial disease vol. 1 (2001), Prominent Press, Scottsdale 143-147
6. Bhagavan H.N., Chopra R.K., Craft N.E., Chitchumroonchokchai C., and Failla M.L. Assessment of coenzyme Q10 absorption using an in vitro digestion-Caco-2 cell model. Int. J. Pharmaceut. 333 (2007) 112-117
7. Chopra R.K., and Bhagavan H.N. Antioxidant nutrient interactions in human subjects. J. Am. Coll. Nutr. 18 (1999) 544
8. Chopra R.K., Goldman R., Sinatra S.T., and Bhagavan H.N. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int. J. Vitam. Nutr. Res. 68 (1998) 109-113
9. Craft N.E., Tucker R.T., Chitchumroonchokchai C., Failla M., and Bhagavan H.N. Assessment of coenzyme Q10 bioavailability using a coupled in vitro digestion/Caco-2 human intestinal cell model. FASEB J. 19 (2005) A449
10. Crane F.L. Biochemical functions of coenzyme Q10. J. Am. Coll. Nutr. 20 (2001) 591-598
11. DiMauro S., Hirano M., and Schon E.A. Approaches to the treatment of mitochondrial diseases. Muscle Nerve 34 (2006) 265-283
12. Elshershari H., Ozer S., Ozkutlu S., and Ozme S. Potential usefulness of coenzyme Q10 in the treatment of idiopathic dilated cardiomyopathy in children. Int. J. Cardiol. 88 (2003) 101-102
13. Ernster L., and Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta 1271 (1995) 195-204
14. Ferrante K.L., Shefner J., Zhang H., Betensky R., O'Brien M., Yu H., Fantasia M., Taft J., Beal M.F., Traynor B., Newhall K., Donofrio P., Caress J., Ashburn C., Freiberg B., O'Neill C., Paladenech C., Walker T., Pestronk A., Abrams B., Florence J., Renna R., Schierbecker J., Malkus B., and Cudkowicz M. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65 (2005) 1834-1836
15. Greenberg S., and Frishman W.H. Co-enzyme Q10: A new drug for cardiovascular disease. J. Clin. Pharmacol. 30 (1990) 596-608
16. Groneberg D.A., Kindermann B., Althammer M., Klapper M., Vormann J., Littarru G.P., and Doring F. Coenzyme Q10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells. Int. J. Biochem. Cell Biol. 37 (2005) 1208-1218
17. Ikematsu H., Nakamura K., Harashima S., Fujii K., and Fukutomi N. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial. Regul. Toxicol. Pharmacol. 44 (2006) 212-218
18. Henriksen J.E., Andersen C.B., Hother-Nielsen O., Vaag A., Mortensen S.A., and Beck-Nielsen H. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus. Diabet. Med. 16 (1999) 312-318
19. Hofman-Bang C., Rehnqvist N., Swedberg K., Wiklund I., and Astrom H. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. J. Card. Fail. 1 (1995) 101-107
20. Hosoe K., Kitano M., Kishida H., Kubo H., Fujii K., and Kitahaara M. Study on safety and bioavailability of ubiquinol (Kaneka QH™) after single and 4-week multiple oral administration to healthy volunteers. Regul. Toxicol. Phamacol. 47 (2007) 19-28
21. Kaikkonen J., Nyyssonen K., Porkkala-Sarataho E., Poulsen H.E., Metsa-Ketela T., Hayn M., Salonen R., and Salonen J.T. Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL+LDL fraction: absorption and antioxidative properties of oil and granule-based preparations. Free Radic. Biol. Med. 22 (1997) 1195-1202
22. Kaikkonen J., Nyyssonen K., Tuomainen T.P., Ristonmaa U., and Salonen J.T. Determinants of plasma coenzyme Q10 in humans. FEBS Lett. 443 (1999) 163-166
23. Kaikkonen J., Nyyssonen K., Tomasi A., Iannone A., Tuomainen T.-P., Porkkala-Sarataho E., and Salonen J.T. Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study. Free Radic. Res. 33 (2000) 329-340
24. Kaikkonen J., Tuomainen T.-P., Nyyssonen K., and Salonen J.T. Coenzyme Q10: absorption, antioxidative properties, determinants, and plasma levels. Free Radic. Res. 36 (2002) 389-397
25. Khatta M., Alexander B.S., Krichten C.M., Fisher M.L., Freudenberger R., Robinson S.W., and Gottlieb S.S. The effect of coenzyme Q10 in patients with congestive heart failure. Ann. Intern. Med. 132 (2000) 636-640
26. Kieburtz K., and The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57 (2001) 397-404
27. Langsjoen P.H., and Langsjoen A.M. Coenzyme Q10 in cardiovascular disease with special emphasis on heart failure and myocardial, ischemia. Asia Pacific Heart J. 7 (1998) 160-168
28. Langsjoen P.H., and Langsjoen A.M. Overview of the use of coenzyme Q10 in cardiovascular disease. Biofactors 9 (1999) 273-284
29. Littarru G.P., and Tiano L. Clinical aspects of coenzyme Q10: an update. Curr. Opin. Clin. Nutr. Metab. Care 8 (2005) 641-646
30. Lonnrot K., Metsa-Ketela T., Molnar G., Ahonen J.P., Latvala M., Peltola J., Pietila T., and Alho H. The effect of ascorbate and ubiquinone supplementation on plasma and CSF total antioxidant capacity. Free Radic. Biol. Med. 21 (1996) 211-217
31. Lu W.-L., Zhang Q., Lee H.-S., Zhou T.-Y., Sun H.-D., Zhang D.-W., Zheng L., Lee M., and Wong S.-M. Total coenzyme Q10 concentrations in Asian men following multiple oral 50-mg doses administered as coenzyme Q10 sustained release tablets or regular tablets. Biol. Pharm. Bull. 26 (2003) 52-55
32. Lucker P.W., Wetzelsberger N., Hennings G., and Rehn D. Pharmacokinetics of coenzyme ubidecarenone in healthy volunteers. In: Folkers K., and Yamamura Y. (Eds). Biomedical and Clinical Aspects of Coenzyme Q vol. 4 (1984), Elsevier, Amsterdam 141-151
33. Miles M.V., Horn P., Miles L., Tang P., Steele P., and DeGrauw T. Bioequivalence of coenzyme Q10 from over-the-counter supplements. Nutr. Res. 22 (2002) 919-929
34. Miles M.V., Horn P.S., Morrison J.A., Tang P.H., DeGrauw T., and Pesce A.J. Plasma coenzyme Q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults. Clin. Chim. Acta 332 (2003) 123-132
35. Miles L., Miles M.V., Tang P.H., Horn P.S., Quinlan J.G., Wong B., Wenisch A., and Bove K.E. Ubiquinol: a potential biomarker for tissue energy requirements and oxidative stress. Clin. Chim. Acta 360 (2005) 87-96
36. Miles M.V., Patterson B.J., Schapiro M.B., Hickey F.J., Chalfonte-Evans M., Horn P.S., and Hotze S.L. Coenzyme Q10 absorption and tolerance in children with Down syndrome: a dose-ranging trial. Pediatr. Neurol. 35 (2006) 30-37
37. Mohr D., Bowry V.W., and Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim. Biophys. Acta 1126 (1992) 247-254
38. Mohr D., Umeda Y., Redgrave T.G., and Stocker R. Antioxidant defenses in rat intestine and mesenteric lymph. Redox Rep. 4 (1999) 79-87
39. Molyneux S., Florkowski C., Lever M., and George P. The bioavailability of coenzyme Q10 supplements available in New Zealand differs markedly. N.Z. Med. J. 117 (2004) U1108
40. Overvad K., Diamant B., Holm L., Holmer G., Mortensen S.A., and Stender S. Coenzyme Q10 in health and disease. Eur. J. Clin. Nutr. 53 (1999) 764-770
41. Permanetter B., Rossy W., Klein G., Weingartner F., Seidl K.F., and Blomer H. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur. Heart J. 13 (1992) 1528-1533
42. Rosenfeldt F., Marasco S., Lyon W., Wowk M., Sheeran F., Bailey M., Esmore D., Davis B., Pick A., Rabinov M., Smith J., Nagley P., and Pepe S. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J. Thorac. Cardiovasc. Surg. 129 (2005) 25-32
43. Serebruany V.L., Ordonez J.V., Herzog W.R., Rohde M., Mortensen S.A., Folkers K., and Gurbel P.A. Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J. Cardiovasc. Pharmacol. 29 (1997) 16-22
44. Shults C.W. Coenzyme Q10 in neurodegenerative diseases. Curr. Med. Chem. 10 (2003) 1917-1921
45. Shults C.W., Beal M.F., Song D., and Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp. Neurol. 188 (2004) 491-494
46. Shults C.W., Oakes D., Kieburtz K., Beal F.L., Haas R., Plumb S., Juncos J.L., Nutt J., Shoulson I., Carter J., Kompoliti K., Perlmutter J.S., Reich S., Stern M., Watts R.L., Kurlan R., Molho E., Harrison M., Lew M., and The Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson Disease. Arch. Neurol. 59 (2002) 1541-1550
47. Shults C.W., Beal M.F., Fontaine D., Nakano K., and Haas R.H. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 50 (1998) 793-795
48. Singh R.B., Niaz M.A., Kumar A., Sindberg C.D., Moesgaard S., and Littarru G.P. Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men. Biofactors 25 (2005) 219-224
49. Steele P.E., Tang P.H., DeGrauw A.J., and Miles M.V. Clinical laboratory monitoring of coenzyme Q10 use in neurologic and muscular diseases. Am. J. Clin. Pathol. 121 (2004) S113-S120
50. Tang P.H., Miles M.V., DeGrauw A., Hershey A., and Pesce A. HPLC analysis reduced and oxidized coenzyme Q(10) in human plasma. Clin. Chem. 47 (2001) 256-265
51. Tomono Y., Hasegawa J., Seki T., Motegi K., and Morishita N. Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int. J. Clin. Phramacol. Ther. Toxicol. 24 (1986) 536-541
52. Watson P.S., Scalia G.M., Galbraith A., Burstow D.J., Bett N., and Aroney C.N. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J. Am. Coll. Cardiol. 33 (1999) 1549-1552
53. Weber C., Bysted A., and Holmer G. Intestinal absorption of coenzyme Q10 administered in a meal or as capsules to healthy subjects. Nutr. Res. 17 (1997) 941-945
54. Weber C., Bysted A., and Holmer G. The coenzyme Q10 content of the average Danish diet. Int. J. Vitam. Nutr. Res. 67 (1997) 123-129
55. Weber C., Jacobsen T.S., Mortensen S.A., Paulsen G., and Homer G. Antioxidative effect of dietary coenzyme Q10 in human blood plasma. Int. J. Vit. Nutr. Res. 64 (1994) 311-315
56. Weis M., Mortensen S.A., Rassing M.R., Moller-Sonnergaard J., Poulsen G., and Rasmussen S.N. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol. Aspects Med. 15 Suppl (1994) s273-s280
57. Yamashita S., and Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal. Biochem. 250 (1997) 66-73
58. Zaghloul A.A., Gurley B., Khan M., Bhagavan H., Chopra R., and Reddy I. Bioavailability assessment of oral coenzyme Q10 formulations in dogs. Drug Dev. Ind. Pharm. 28 (2002) 1195-1200
59. Zhang Y., Aberg F., Appelkvist E.L., Dallner G., and Ernster L. Uptake of dietary coenzyme Q supplement is limited in rats. J. Nutr. 125 (1995) 446-453
60. Zita C., Overvad K., Mortensen S.A., Sindberg C.D., Moesgaard S., and Hunter D.A. Serum coenzyme Q10 concentrations in healthy men supplemented with 30 mg or 100 mg coenzyme Q10 for two months in a randomised controlled study. Biofactors 18 (2003) 185-193